Eesti - eesti - Ravimiamet

ranbaxy (u.k.) limited - esomeprasool - gastroresistentne tablett - 40mg 98tk; 40mg 60tk; 40mg 15tk; 40mg 30tk; 40mg 50tk; 40mg 56tk; 40mg 100tk; 40mg 28tk; 40mg 7tk

Eesti - eesti - Ravimiamet

ranbaxy (u.k.) limited - esomeprasool - gastroresistentne tablett - 20mg 90tk; 20mg 15tk; 20mg 28tk; 20mg 14tk; 20mg 7tk; 20mg 56tk; 20mg 30tk; 20mg 60tk

Eesti - eesti - Ravimiamet

pfizer europe ma eeig - naatriumdaltepariin - süstelahus süstlis - 2500rÜ anti xa 0.2ml 0.2ml 10tk

Eesti - eesti - Ravimiamet

pfizer europe ma eeig - naatriumdaltepariin - süstelahus süstlis - 5000rÜ anti xa 0.2ml 0.2ml 10tk

Eesti - eesti - Ravimiamet

pfizer europe ma eeig - naatriumdaltepariin - süstelahus süstlis - 10000rÜ anti xa 0.4ml 0.4ml 5tk

Eesti - eesti - Ravimiamet

vetoquinol biowet sp. z o.o. - ketamiin - süstelahus - 100mg 1ml 50ml 1tk; 100mg 1ml 10ml 1tk

Eesti - eesti - Ravimiamet

pfizer europe ma eeig - naatriumdaltepariin - süstelahus süstlis - 7500rÜ anti xa 0.3ml 10tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Euroopa Liit - eesti - EMA (European Medicines Agency)

theramex ireland limited - linzagolix choline - leiomüoom - hüpofüüsi ja hüpotaalamuse hormoonid ja analoogid - yselty is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.